Overview

An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine. The current study is to provide 12 months post study access to open-label lamotrigine for participants of the SCA101469 study.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Anticonvulsants
Lamotrigine